Runx1 repression by histone deacetylation is critical for Setbp1-induced mouse myeloid leukemia development
Abnormal activation of SETBP1 through overexpression or missense mutations is highly recurrent in various myeloid malignancies; however, it is unclear whether such activation alone is able to induce leukemia development. Here we show that Setbp1 overexpression in mouse bone marrow progenitors throug...
Saved in:
Published in | Leukemia Vol. 30; no. 1; pp. 200 - 208 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
Nature Publishing Group UK
01.01.2016
Nature Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Abnormal activation of
SETBP1
through overexpression or missense mutations is highly recurrent in various myeloid malignancies; however, it is unclear whether such activation alone is able to induce leukemia development. Here we show that
Setbp1
overexpression in mouse bone marrow progenitors through retroviral transduction is capable of initiating leukemia development in irradiated recipient mice. Before leukemic transformation,
Setbp1
overexpression significantly enhances the self-renewal of hematopoietic stem cells (HSCs) and expands granulocyte macrophage progenitors (GMPs). Interestingly,
Setbp1
overexpression also causes transcriptional repression of critical hematopoiesis regulator gene
Runx1
and this effect is crucial for Setbp1-induced transformation.
Runx1
repression is induced by Setbp1-mediated recruitment of a nucleosome remodeling deacetylase (NuRD) complex to
Runx1
promoters and can be reversed by treatment with histone deacetylase (HDAC) inhibitors Entinostat and Vorinostat. Moreover, treatment with these inhibitors caused efficient differentiation of
Setbp1
activation-induced leukemia cells
in vitro
, and significantly extended the survival of mice transplanted with such leukemias, suggesting that HDAC inhibition could be an effective strategy for treating myeloid malignancies with
SETBP1
activation. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally to this work. |
ISSN: | 0887-6924 1476-5551 |
DOI: | 10.1038/leu.2015.200 |